Heart Failure
Palliative care may reduce readmissions, mechanical ventilation for HF
Veterans who received palliative care during HF admissions had less mechanical ventilation and fewer readmissions compared with those who did not, according to findings in the Journal of the American Heart Association.
Clinical distancing of patients with advanced HF, transplant may protect against COVID-19
One hospital system protected its patients with advanced HF and cardiac transplant from COVID-19 by safely moving them from a central hospital, which was redesigned to care for patients with COVID-19, to a cardiac specialty hospital with no patients with COVID-19, according to a paper published in The Journal of Heart and Lung Transplantation.
No difference by hospital volume in events after TAVR for bicuspid aortic valves
Low- and high-volume hospitals that performed transcatheter aortic valve replacement for bicuspid aortic valves had similar rates of in-hospital and 30-day outcomes, researchers reported.
Managing CV toxicities of targeted antiangiogenesis therapies
Clinical outcomes for patients with malignancies have improved in the past decade, in part due to the emergence of VEGF inhibitors.
ENABLE CHF-PC
Effects of a behavioral support program for palliative care in caregivers of patients with advanced HF.
Medicaid expansion improves HF therapy administration for certain racial/ethnic groups
The Affordable Care Act Medicaid Expansion increased receipt of ACE inhibitors, angiotensin II receptor antagonists and angiotensin receptor-neprilysin inhibitors for Hispanic patients hospitalized for HF, according to data presented at the virtual American Heart Association Quality of Care and Outcomes Research Scientific Sessions.
FDA OKs dapagliflozin for heart failure regardless of diabetes status, plus more top stories in cardiology
Novel myosin activator for HFrEF nets FDA fast track designation
Amgen and Cytokinetics announced that the FDA has granted a fast track designation to omecamtiv mecarbil, the companies’ novel selective cardiac myosin activator developed for the treatment of chronic HF with reduced ejection fraction.
AHA: Assessment of social determinants of health can improve HF care
Cardiologists and other health care providers should keep in mind a patient’s social determinants such as living environment, race and income inequality during treatment for HF, according to an American Heart Association scientific statement published in Circulation.
Pregnancy complications may yield future HF risk
A history of adverse pregnancy outcomes, particularly low birth weight, increased risk for HF, according to data presented at the virtual American College of Cardiology Scientific Session.